



LISA TRACKER® launched in the US market

- Four biotherapy monitoring tests being marketed by Miraca Life Sciences
- The largest range of tests available in the US market

Croissy-Beaubourg and Montpellier, June 16, 2016 – Theradiag (ISIN: FR0004197747, Ticker: ALTER, eligible for PEA-PME savings plans), a company specializing in *in vitro* diagnostics and theranostics, announced today that four tests from its LISA TRACKER® range have been launched in the US market, under the licensing agreement with Miraca Life Sciences that was announced in November 2015¹.

Miraca Life Sciences will start to market and promote four tests under the name “[InformTx™](#)” that utilize technology and raw materials from Theradiag's LISA TRACKER® range. These four biotherapy monitoring tests (*Infliximab*/Remicade®, *Adalimumab*/Humira®, *Certolizumab*/Cimzia® and *Vedolizumab*/Entyvio®) deal mainly with inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis. The launch of InformTx™ by Miraca Life Sciences marks the first time that monitoring has been available in the US market for *Certolizumab* and *Vedolizumab*. No other US medical laboratory offers the full set of these monitoring tests, giving Miraca Life Sciences a substantial competitive advantage.

The tests have undergone rigorous validations in Miraca Life Sciences' CLIA-certified and CAP-accredited² laboratory, located in Phoenix, Arizona.

It is estimated more than 330,000 IBD patients in the United States are treated with biologics³, two times more than in Europe.

Theradiag will sell the required materials and will receive royalties on Miraca Life Sciences' sales in the USA.

"Miraca Life Sciences' launch of our first four tests in the USA is a major milestone in our geographical expansion strategy and represents a source of large potential sales in the years to come. Its expertise and knowledge of the US market make it the ideal partner to develop our LISA TRACKER® range in the United States. The partnership enables us to make our biotherapy monitoring tests available to US clinicians, helping them to optimise biotherapy treatments," said Michel Finance, CEO of Theradiag.

About Theradiag

Capitalizing on its expertise in the distribution, development and manufacturing of *in vitro* diagnostic tests, Theradiag innovates and develops theranostics tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag notably markets the Lisa Tracker® range (CE marked), which is a comprehensive multiparameter theranostic solution for patients with autoimmune diseases treated with biotherapies. With its subsidiary Prestizia, Theradiag is developing new biomarkers based on microRNAs for the diagnosis and monitoring of rectal cancer, auto-immune and inflammatory diseases and HIV/AIDS. Theradiag is thus participating in the development of customized

¹ See press release of 18 November 2015: [Theradiag announces strategic agreement with Miraca Life Sciences in the USA](#)

² CAP : College of American Pathologists :

http://www.cap.org/web/home?_afLoop=494564010322532#!%40%40%3F_afLoop%3D494564010322532%26_adf.ctrl-state%3Dj8l7h68sd_4

³ Epidemiology of IBD in the US, Datamonitor 2015

treatment, which favors the individualization of treatments, the evaluation of their efficacy and the prevention of drug resistance. The Company is based in Marne-la-Vallée, near Paris, and in Montpellier, and has over 75 employees.

For more information about Theradiag, please visit our website: www.theradiag.com



Theradiag

Investor Relations

Fabienne François

CFO

+33 1 64 62 10 12

contact@theradiag.com

NewCap

Financial communications/
investor relations

Valentine Brouhot/

Pierre Laurent

+33 1 44 71 94 94

theradiag@newcap.eu

Alize RP

Press

Caroline Carmagnol/

Florence Portejoie

+33 1 44 54 36 64

theradiag@alizerp.com